There are about 28871 clinical studies being (or have been) conducted in Canada. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
This global study (US, Canada, and Australia) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric subjects utilizing Fiasp (insulin aspart injection) in a home setting.
Repetitive Transcranial magnetic stimulation (TMS) uses magnetic fields to modulate brain activity. A novel form of repetitive TMS (rTMS), intermittent theta burst stimulation (iTBS), has emerged as a promising new treatment for depression. This technique may be advantageous due to its very short duration and potentially stronger effect on brain activity in comparison with standard rTMS. However, the exact effect of iTBS on the activity of the brain in clinical populations remains poorly understood. This project aims to improve understanding of the mechanisms of action of iTBS by comparing its neuronal effect to sham treatment in 22 individuals with a diagnosis of major depressive episode, using positron emission tomography (PET) and magnetic resonance imaging (MRI) in a double-blind cross-over experiment, followed by a 6-week daily treatment course of iTBS.
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab.
The Boppli device was designed to provide continuous non-invasive blood pressure (cNIBP) monitoring for infants, including neonates, in intensive care settings by detecting systolic, diastolic, and mean arterial blood pressure values comparable to that of an invasive arterial line (IAL) within published accuracy criteria. The device consists of an array of capacitive sensors contained in a soft, flexible, biocompatible band. It applies proprietary algorithms to capacitance detections to generate accurate systolic, diastolic, and mean arterial blood pressure and waveform data, then communicates the data to an external device via Bluetooth Low Energy for storage and display. It may be applied to the patient's arm or foot on either side of the body, which is advantageous for infants whose bodies provide limited surface area for medical devices or equipment. It does not require high skin pressure when correctly placed. The device is intended for single use of up to 72 hours and is discarded following use.
Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
The SYNAPSE trial is designed to study the effects of an individualized home-based cognitive training program on cognitive functions in heart-failure patients.
Emotional eating, or overeating in response to emotions, is problematic because of its link to weight gain, obesity, and psychopathology such as bulimia and binge eating disorder. To date, a vast amount of research has studied the psychological processes that cause individuals to overeat in response to emotions in an effort to develop ways to help individuals reduce their emotional eating. The aim of the current project is to study two psychological processes that can potentially be positively influenced to improve well-being: perceived body boundaries and a person's spatial frame of reference. Particularly, the investigators will examine how perceived body boundaries and spatial frames of reference can be positively influenced through a body scan meditation and thereby improve emotional eating. Perceived body boundaries refers to the continuum along which the self is experienced, from a body-encapsulated entity that is separate from the surrounding world to a more diffuse entity that is more connected with others and the environment. Spatial frames of reference describes the region within one's perception, often based in the body and construed as the self, that may be experienced as egocentric, through a preoccupation with internal events, or as allocentric, with feelings of unity and interdependence with others and the environment. One way for individuals to experience more diffuse body boundaries and allocentric frames of reference is through a body scan meditation. In this practice, individuals are instructed to intentionally shift their attention to various parts of the body and to notice what happens without judging or reacting. Thoughts and emotions are briefly noted if they arise, and attention is shifted back to the body. Recent research has shown that when individuals practice the body scan meditation, individuals are likely to experience greater positive emotions, lower negative emotions, lower ruminations, and higher psychological wellbeing. In addition, research has shown that individuals are able to experience more diffuse perceived body boundaries and more allocentric frames of reference through a body scan meditation. Based on this work, the researchers predict that when emotional eaters practice the body scan meditation, emotional eaters will experience more diffuse body boundaries, more allocentric frames of reference, and lower ruminations, which could in turn reduce their negative affect and food cravings. The researchers will test this hypothesis by asking emotional eaters to complete questionnaires that measure perceived body boundaries, spatial frames of reference, ruminations, negative emotions, and food cravings before and after a body scan meditation. To ensure that any changes in these measures are due to the meditation, the researchers will compare these findings with emotional eaters who complete the same measures before and after a control listening task. The findings of the current study will be used to recommend the body scan meditation to support emotional eaters in regulating their emotions, cravings, and eating behaviors.
This is a parallel arm, Phase 3, double-blind, double-dummy, active-comparator, 2 arm study to evaluate the efficacy and safety of daily oral venglustat versus intravenous Cerezyme infusions every two weeks for improvement or stabilization of the neurological manifestations and maintenance of systemic disease stability in participants aged ≥12 and <18 years and adult patients with Gaucher disease Type 3 (GD3) who have been treated with Enzyme Replacement Therapy (ERT) for at least 3 years.
Vasomotor symptoms (VMS) are a common consequence of systemic therapies for breast cancer. Breast cancer treatments can cause VMS in approximately 30% of postmenopausal women and 95% of premenopausal women with early stage breast cancer (EBC). There are many non-estrogen-based interventions available to manage VMS, including; lifestyle modifications, complementary and alternative medicine (CAM) therapies. However, a recent systematic review and meta-analysis of pharmacological and CAM interventions conducted by our team, found no single optimal treatment for VMS management in breast cancer patients. Given the complex patient, cancer and treatment variables influencing the experience of VMS, the numerous potentially effective VMS interventions available and the varying expectations for an effective intervention, the investigators believe Machine Learning (ML) is ideally suited to the analysis of this common and bothersome treatment related toxicity. The EPIC electronic medical record, and MyChart application has provided both clinicians and patients with increased tools for the documentation of health related outcomes. The investigators believe that the MyChart platform, and ML techniques can be utilized to collect, and analyze outcome data for breast cancer patients experiencing VMS.
The phase 1b study is aimed at determining the pediatric recommended phase 2 dose (RP2D) of Infigratinib. The phase 2 study will evaluate efficacy and safety of infigratinib.